# MAPT (Microtubule-Associated Protein Tau) — Target Profile
## Overview
Microtubule-Associated Protein Tau (MAPT) is central to Alzheimer's disease and tauopathies. Tau stabilizes microtubules but hyperphosphorylation causes aggregation into neurofibrillary tangles. Six isoforms (3R/4R) exist with distinct disease associations. Tau pathology correlates with cognitive decline more strongly than amyloid plaques, making it a prime therapeutic target.
**Target class: Structural Protein** — Tau is an intrinsically disordered protein that adopts pathological conformations during disease. While historically challenging to drug, cryo-EM structures of disease-specific tau filament folds have enabled conformation-selective therapeutic approaches.
## Druggability Analysis
This target has a **medium druggability** profile. Multiple therapeutic modalities are being explored including anti-tau antibodies, aggregation inhibitors, antisense oligonucleotides (ASOs), and kinase inhibitors targeting tau phosphorylation.
**Druggability score:** 0.65 (65th percentile) — Target shows moderate druggability with multiple active clinical programs.
## Clinical Pipeline
**Phase 3:**
- **LMTX (TRx0237)** — Tau aggregation inhibitor for Alzheimer's disease
**Phase 2:**
- **Semorinemab** — Anti-tau antibody for Alzheimer's disease
- **Bepranemab** — Anti-tau antibody targeting mid-domain tau
**Phase 1/Preclinical:**
- **Tilavonemab** — Anti-tau antibody (N-terminal)
- **BIIB080 (IONIS-MAPTRx)** — Antisense oligonucleotide reducing tau expression
## Structural Biology
134 PDB structures available, including cryo-EM structures of disease-specific tau filament folds. AlphaFold predicted structure also available. Cryo-EM revealed that different tauopathies feature distinct filament conformations, enabling conformation-selective drug design.
## SciDEX Research Context
- One of the most studied targets in the neurodegeneration portfolio
- Strong knowledge graph connectivity to Alzheimer's disease pathways
- Multiple hypotheses in the SciDEX Exchange involve tau-related mechanisms
Druggability Rationale:MAPT demonstrates medium druggability (0.65) with multiple clinical candidates in Phase 2/3 trials, supported by 134 PDB structures and AlphaFold models enabling structure-based design. However, as a structural protein lacking a traditional catalytic pocket, it is best targeted through antibody-based approaches, aggregation inhibitors, and indirect modulation rather than small-molecule active site binders, which explains the moderate druggability score despite robust structural information.
Mechanism:Tau aggregation inhibitors, anti-tau antibodies, tau phosphorylation modulators
While MAPT lacks a traditional active site, structural data reveals tau's microtubule-binding domains and proline-rich regions as targetable regions for aggregation inhibitors like LMTX; antibody therapeutics bind conformational epitopes on monomeric or oligomeric tau species, exploiting the extensive structural information from 134 PDB entries to map disease-relevant epitopes and aggregation interfaces.
Selectivity & Safety Considerations
A major challenge is achieving selectivity between tau isoforms (3R vs 4R tau), as different tauopathies preferentially aggregate specific isoforms; antibody-based therapies can achieve epitope selectivity but small-molecule aggregation inhibitors may lack isoform discrimination. Off-target phosphorylation modulation is a concern, as kinase inhibitors targeting tau phosphorylation regulators may affect multiple kinase pathways with broader CNS effects.